Melatonin is not classified as a hepatotoxin, and at standard doses it does not appear to damage healthy liver tissue. The bulk of research actually points in the opposite direction: in animal models and small human trials, melatonin has shown protective effects on the liver. But “not hepatotoxic” is not the same as “risk-free for everyone.” A handful of case reports link melatonin to flare-ups of autoimmune liver disease, and a recently halted clinical trial found liver enzyme elevations when high-dose melatonin was combined with other heavily metabolized drugs. The story is more complicated than either “perfectly safe” or “dangerous,” and the details matter if you already have liver disease, take certain medications, or use melatonin at doses well above what your body produces on its own.
How Your Liver Processes Melatonin
Whether you take it as a pill or your pineal gland secretes it at night, melatonin travels to the liver, where it gets broken down primarily by a single enzyme called CYP1A2. This enzyme converts melatonin into a compound called 6-hydroxymelatonin, which your kidneys then flush out. Multiple studies have confirmed that CYP1A2 is the main workhorse here, though other enzymes play minor supporting roles.1PubMed. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes This matters because anything that slows down or speeds up CYP1A2 changes how much melatonin ends up circulating in your blood.
When you swallow a melatonin tablet, the liver intercepts a large fraction of it before it ever reaches the rest of your body. Researchers describe this as a “high hepatic extraction ratio,” which is a technical way of saying the liver is very efficient at grabbing melatonin on the first pass.2PubMed. Pharmacokinetics of melatonin in man: first pass hepatic metabolism Studies using 2 and 4 mg oral doses found that the actual amount reaching the bloodstream was quite low, likely because of this aggressive first-pass metabolism.3PubMed. The absolute bioavailability of oral melatonin This is important context: the liver deals with oral melatonin quickly and thoroughly under normal conditions, which helps explain why standard doses rarely cause problems.
The Protective Side of Melatonin
Ironically, given the question in the title, the vast majority of liver-related melatonin research is about melatonin protecting the liver, not harming it. Melatonin is a potent antioxidant, and the liver is an organ constantly exposed to oxidative stress from processing toxins, drugs, and metabolic byproducts. Studies have found that melatonin can regulate inflammation, reduce cell death, and influence several molecular pathways relevant to liver health.4PubMed Central. Effects of Melatonin on Liver Injuries and Diseases
In animal models of alcohol-related liver disease, melatonin reduced liver enzyme levels, decreased fat accumulation in liver cells, and dialed down the inflammatory response. Immune cells in the liver called Kupffer cells, which tend to pump out damaging molecules during heavy alcohol exposure, produced fewer of those molecules when the animals received melatonin.5PubMed. Melatonin protects against alcoholic liver injury by attenuating oxidative stress, inflammatory response, and apoptosis More recent work suggests melatonin can also protect against liver damage from ischemia-reperfusion injury, the kind of damage that occurs when blood flow to the liver is temporarily cut off and then restored, as can happen during surgery or organ transplantation.6PubMed Central. Melatonin attenuates liver ischemia-reperfusion injury via inhibiting the PGAM5-mPTP pathway Researchers have also found that melatonin reduced liver fibrosis caused by particulate matter exposure by activating protective cellular pathways and tamping down oxidative stress.7PubMed. Melatonin alleviates particulate matter-induced liver fibrosis by inhibiting ROS-mediated mitophagy and inflammation via Nrf2 activation
This body of evidence is large enough that some researchers have proposed melatonin as a therapeutic tool for various liver conditions. But nearly all of this work comes from animal experiments or cell cultures, and the doses used in lab animals often don’t translate directly to what humans would take. The protective findings are encouraging, but they do not mean that more melatonin is always better for your liver.
Melatonin and Fatty Liver Disease
Non-alcoholic fatty liver disease is one area where human trials have actually tested melatonin. In a randomized, double-blind trial, patients who received 6 mg of melatonin per day saw improvements in liver enzyme levels, markers of inflammation, weight, waist circumference, and the severity of fatty liver on imaging, compared to a placebo group.8PubMed. The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial A separate trial reported similar results: fatty liver grading improved significantly in the melatonin group, with greater decreases in the liver enzyme AST and in an inflammation marker.9PubMed Central. The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial
A meta-analysis pooling data from multiple randomized trials of melatonin in fatty liver patients found that melatonin supplementation improved several liver enzyme markers, though it did not significantly affect all of them equally.10PubMed. The effect of melatonin supplementation on liver indices in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized clinical trials These trials are small and short-term, so they are far from definitive. But they do suggest that standard-dose melatonin is not damaging the liver in this population and may even help. For people who stumble across warnings about melatonin and liver harm, this is useful counter-evidence.
When Melatonin Has Been Linked to Liver Problems
The cases where melatonin has been associated with liver trouble share a common thread: autoimmune liver disease. Autoimmune hepatitis is a condition in which the immune system attacks the liver, and melatonin has known immunostimulatory properties, meaning it can amp up certain immune responses. A 1997 case report described a patient who developed autoimmune hepatitis after beginning melatonin therapy for insomnia, with liver biopsy confirming the diagnosis.11PubMed. Is melatonin associated with the development of autoimmune hepatitis?
Additional cases have surfaced since then. A patient with primary sclerosing cholangitis, a chronic autoimmune bile-duct disease, started taking 5 mg of melatonin nightly for sleep. About three weeks later, routine blood tests showed a dramatic spike in liver enzymes, with ALT and AST jumping to roughly ten and eight times the upper limit of normal, respectively. The treating physicians concluded this was not direct liver toxicity from melatonin but rather an immune-mediated flare of the patient’s underlying disease triggered by melatonin’s immunostimulatory effects. Enzyme levels dropped significantly within a month of stopping the supplement.12PubMed Central. A case of melatonin-induced biochemical flare in a patient with primary sclerosing cholangitis with features of autoimmune hepatitis Similar case reports exist for ramelteon, a prescription drug that acts on melatonin receptors.13PubMed Central. Benefits and Risks of Melatonin in Hepatic and Pancreatic Disorders; A Review of Clinical Evidences
A conference abstract from the journal Sleep highlighted another case of melatonin-induced autoimmune hepatitis and emphasized that while uncommon, the immunostimulatory properties of melatonin are sometimes overlooked by clinicians who view it as entirely harmless. The authors recommended that melatonin use in people with autoimmune disorders should be documented and monitored carefully.14Sleep. Melatonin Induced Autoimmune Hepatitis in the Setting of the Management of REM Sleep Behavior Disorder To be clear, these are isolated case reports, not large studies. They do not prove that melatonin causes autoimmune hepatitis in any general sense. But if you have an existing autoimmune liver condition, they are worth knowing about.
The High-Dose Trial That Had to Stop
Perhaps the strongest caution sign comes from a recent clinical trial called MELATOMS-1, which tested high-dose melatonin (the specific doses were well above typical over-the-counter amounts) as an add-on therapy in patients receiving ocrelizumab for primary progressive multiple sclerosis. The trial was stopped early after only eight patients had been enrolled because three of the four patients in the melatonin arm developed elevated liver enzymes, a condition called hypertransaminasemia. All three were women taking multiple other medications that share hepatic metabolism pathways with melatonin. Their enzyme levels returned to normal after melatonin was discontinued.15PubMed Central. Hepatic Safety of Adjunctive High-Dose Melatonin in Participants Receiving Ocrelizumab for Primary Progressive Multiple Sclerosis: Liver Toxicity Findings from a Phase I/II Randomised Clinical Trial (MELATOMS-1)
The one male participant in the melatonin arm, who was not taking medications that competed for the same liver pathways, had no liver-related problems during more than a year of treatment. The researchers interpreted this pattern as suggestive of a metabolic traffic jam: when several drugs and melatonin are all vying for the same liver enzymes, the liver can become overloaded, leading to a buildup of metabolites that cause damage. This is not melatonin being inherently toxic. It is melatonin, at high doses, overwhelming the liver’s processing capacity when other drugs are already occupying the same metabolic machinery.
Drug Interactions That Multiply Melatonin Levels
Because melatonin is so dependent on CYP1A2 for clearance, any drug that inhibits that enzyme can dramatically increase the amount of melatonin in your system. The most striking example is fluvoxamine, an antidepressant and strong CYP1A2 inhibitor. When researchers gave fluvoxamine alongside oral melatonin, the melatonin blood levels jumped roughly 17-fold compared to melatonin alone.16PubMed. Increased bioavailability of oral melatonin after fluvoxamine coadministration That means a 3 mg melatonin tablet could produce blood levels equivalent to something closer to 50 mg. This effect is so pronounced that oral melatonin has been proposed as a clinical probe to measure CYP1A2 activity.17Clinical Pharmacology & Therapeutics. Orally given melatonin may serve as a probe drug for CYP1A2 activity in vivo
Fortunately, not every common drug creates this problem. One screening study tested several widely used drugs, including diazepam, tamoxifen, and acetaminophen, and found that at normal therapeutic doses, none of them meaningfully impaired melatonin metabolism. Only extremely potent CYP1A2 inhibitors appeared to create clinically relevant interactions.18PubMed. Potential drug interactions with melatonin Still, if you take fluvoxamine or another strong CYP1A2 inhibitor (ciprofloxacin is another well-known one) and also take melatonin, the effective dose you are getting could be vastly higher than what the label says. That elevated exposure is the kind of scenario where the MELATOMS-1 liver findings become relevant.
What Existing Liver Disease Changes
If your liver is already significantly impaired, the equation shifts. In patients with liver cirrhosis, daytime melatonin blood levels are substantially elevated compared to healthy people, and the liver clears melatonin much more slowly. Researchers found that both phases of melatonin clearance were prolonged in cirrhosis patients, likely because of reduced blood flow through the liver, diminished enzyme activity, and competition with bilirubin in the liver’s transport systems.19The Journal of Clinical Endocrinology & Metabolism. Melatonin Serum Levels and Metabolic Clearance Rate in Patients with Liver Cirrhosis In practical terms, a normal dose of melatonin could produce much higher and longer-lasting blood levels in someone with cirrhosis than in someone with a healthy liver.
This doesn’t automatically mean melatonin is harmful for people with cirrhosis. Some of the protective research described earlier is specifically relevant to damaged livers. But it does mean that dosing guidelines developed for people with normal liver function may not apply, and that the risk of accidentally reaching problematically high levels is greater. Anyone with significant liver disease should talk to a doctor before starting melatonin, not because the supplement is a known liver toxin, but because their liver handles it differently.
What Is Actually in the Bottle
There is a wrinkle in this discussion that has nothing to do with melatonin’s pharmacology and everything to do with the supplement industry. In much of the world, melatonin is sold as a dietary supplement rather than a regulated drug, which means manufacturers are not held to the same quality-control standards as pharmaceutical companies. A study that analyzed 31 melatonin supplements found that the actual melatonin content ranged from 83% less to 478% more than what the label claimed. Lot-to-lot variability within a single product was as high as 465%. The researchers also found serotonin, a completely different compound, in about a quarter of the supplements tested.20PubMed Central. Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content
This means that when someone reports a side effect from “melatonin,” they may have actually taken four or five times the intended dose, or they may have ingested contaminants that have their own set of effects. For any discussion of whether melatonin causes liver harm, supplement inconsistency is a confounding factor that is hard to control for. If you’re taking a supplement that contains nearly five times its labeled dose on some nights and a fraction of it on others, your liver is dealing with unpredictable loads. Choosing brands that carry third-party certification (USP, NSF, or ConsumerLab verification) can reduce but not eliminate this variability.
Children and Long-Term Use
Melatonin use in children has risen dramatically, particularly for sleep difficulties associated with autism spectrum disorder and ADHD. Safety reviews of long-term pediatric use, including trials lasting up to two years of continuous treatment, have found that the most common adverse events were fatigue, sleepiness, and mood swings, all at low rates. No significant changes in growth, weight, or pubertal development were observed, and serious adverse effects were not reported.21Kosin Medical Journal. Safety issues regarding melatonin use in child and adolescent patients with sleep problems Liver damage has not emerged as a concern in these pediatric studies. That said, most pediatric trials use moderate doses and carefully screened participants, so the reassurance extends to that context and not to unsupervised high-dose use.
Melatonin and the Biliary System
The liver does not exist in isolation; it connects to the gallbladder and bile ducts through the biliary system, and melatonin shows up there too. Melatonin is present in bile and appears to promote the conversion of cholesterol into bile acids while inhibiting intestinal cholesterol absorption.22PubMed Central. Melatonin’s anti-inflammatory and antioxidant effects in gallstone disease: A narrative review This has led researchers to investigate whether melatonin could play a role in preventing gallstone formation, since gallstones are often composed of crystallized cholesterol. The anti-inflammatory and antioxidant properties that protect liver cells also appear to benefit the biliary tract, at least in the early research. Whether this translates into clinical advice for gallstone-prone individuals remains to be seen, but it is another example of melatonin’s generally positive relationship with the hepatobiliary system at normal physiological levels.
Who Should Be Cautious
Pulling the evidence together, the people who have reason to be careful with melatonin and liver health fall into a few identifiable groups:
- Autoimmune liver disease: If you have autoimmune hepatitis, primary sclerosing cholangitis, or another autoimmune condition affecting the liver, melatonin’s immune-boosting properties could trigger a flare. The case reports are rare but consistent in their mechanism.
- Heavy polypharmacy: If you take multiple medications that rely on the same CYP1A2 pathway, adding high-dose melatonin could create a metabolic bottleneck. The MELATOMS-1 trial is the clearest warning here.
- CYP1A2 inhibitor use: If you take fluvoxamine, ciprofloxacin, or another strong CYP1A2 inhibitor, even a modest melatonin dose could result in dramatically elevated blood levels.
- Advanced liver disease: If you have cirrhosis or severe liver impairment, your liver clears melatonin much more slowly, making standard doses effectively larger.
For the general population taking 1 to 5 mg of melatonin occasionally for sleep, the evidence does not support liver damage as a realistic concern. The liver handles melatonin efficiently, the human trial data in fatty liver disease shows improvement rather than harm, and decades of widespread over-the-counter use have not produced a pattern of liver toxicity reports. The risks live in the margins: specific medical conditions, specific drug combinations, and the wildly inconsistent quality of the supplement supply.